002693 *ST双成药业
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-4.807-18.107-10.3031.811-4.170
总资产报酬率 ROA (%)-2.401-9.868-5.9201.021-2.307
投入资产回报率 ROIC (%)-2.894-12.064-7.2671.278-2.919

边际利润分析
销售毛利率 (%)46.72456.03768.27267.86774.589
营业利润率 (%)-27.536-60.922-31.007-3.280-12.033
息税前利润/营业总收入 (%)-22.039-55.849-26.9130.832-9.515
净利润/营业总收入 (%)-27.381-61.002-30.508-3.092-12.741

收益指标分析
经营活动净收益/利润总额(%)111.68075.68257.871612.935140.514
价值变动净收益/利润总额(%)-1.1878.85150.845-52.175-10.200
营业外收支净额/利润总额(%)0.6080.040-0.255-1.4704.508

偿债能力分析
流动比率 (X)0.6880.8810.9660.7901.526
速动比率 (X)0.2810.4260.4350.5851.017
资产负债率 (%)48.49047.49035.55636.23233.679
带息债务/全部投入资本 (%)38.82637.54525.94329.67325.675
股东权益/带息债务 (%)153.520161.914279.148232.168282.225
股东权益/负债合计 (%)102.502105.681165.085155.585167.422
利息保障倍数 (X)-3.890-10.958-6.7040.205-3.083

营运能力分析
应收账款周转天数 (天)31.27326.67031.35730.81924.177
存货周转天数 (天)321.486363.927335.973245.989238.927